



25 November 2019

The Manager  
Company Announcements Office  
ASX Limited  
Level 6, 20 Bridge Street  
SYDNEY NSW 2000

By: e-lodgement

Dear Sir/Madam

## RESULTS OF ANNUAL GENERAL MEETING


Actinogen Medical Limited (ASX: ACW) advises that its Annual General Meeting of Shareholders was held today at 11.00 am (AEDT).

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that the details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

Yours faithfully

A handwritten signature in black ink, appearing to read "Peter Webse".

**Peter Webse**  
Company Secretary

**Actinogen Medical**  
Dr. Bill Ketelbey  
CEO & Managing Director  
P: +61 2 8964 7401  
E: [bill.ketelbey@actinogen.com.au](mailto:bill.ketelbey@actinogen.com.au)  
 @BillKetelbey

**Investor and Media Enquiries**  
Arthur Chan  
WE Communications  
P: +61 2 9237 2805  
E: [arthurc@we-worldwide.com](mailto:arthurc@we-worldwide.com)

## About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotechnology company focused on innovative approaches to treating cognitive decline that occurs in chronic neurological and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with multibillion-dollar market potential and material human impact. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn and is projected to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia. In addition, Actinogen is currently planning an expanded clinical development program for Xanamem in cognitive impairment in mood disorders and schizophrenia. In the US alone, the collective economic costs of mood disorders and schizophrenia are estimated to exceed \$550bn, with the burden increasing every year. The cognitive dysfunction associated with these conditions is significantly debilitating for affected patients, with a substantial unmet medical need for novel, improved treatments.

### **About Xanamem™**

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory. The 11β-HSD1 enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain associated with cognitive impairment in neurological diseases, including Alzheimer's disease, mood disorders and schizophrenia.

### **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem 10mg daily in subjects with mild dementia due to Alzheimer's disease. XanADu has fully enrolled 186 patients from 25 research sites across Australia, the UK and the USA. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

### **About XanaHES**

XanaHES is a Phase I, randomised, single blinded, central reader blinded, placebo-controlled, dose escalation study to assess the safety and tolerability of Xanamem™ 20mg once daily in healthy elderly volunteers. Changes in cognitive performance from baseline to end-of-treatment are measured as an exploratory efficacy outcome.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**



ANNUAL GENERAL MEETING  
Monday, 25 November, 2019

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution	Manner in which the securityholder directed the proxy vote (as at proxy close):					Manner in which votes were cast in person or by proxy on a poll (where applicable)			
	Votes <i>For</i>	Votes <i>Against</i>	<i>Discretionary Chairman of Meeting</i>	Total Votes <i>Discretionary</i>	Votes <i>Abstain</i>	<i>For</i>	<i>Against</i>	<i>Abstain **</i>	<i>Resolution Result</i>
			<i>Other Nominated Person/s</i>						
1 REMUNERATION REPORT(ADVISORY RESOLUTION)	387,269,660	4,029,597	1,548,744 419,799	1,968,543	3,707,511	404,249,515 99.01%	4,029,597 0.99%	3,707,511	Carried
2 RE-ELECTION OF DIRECTOR: DR GEOFF BROOKE	391,307,024	6,000	5,356,638 419,799	5,776,437	3,528,744	412,405,682 100.00%	6,000 0.00%	3,528,744	Carried
3 ELECTION OF DIRECTOR: MALCOLM MCCOMAS	391,183,201	66,000	5,356,638 419,799	5,776,437	3,592,567	412,281,859 99.98%	66,000 0.02%	3,592,567	Carried
4 RENEWAL OF PROPORTIONAL BID PROVISIONS IN THE CONSTITUTION	390,161,847	835,123	5,211,638 419,799	5,631,437	3,989,798	411,115,505 99.80%	835,123 0.20%	3,989,798	Carried
5 APPROVAL FOR ADDITIONAL 10% PLACEMENT CAPACITY	386,766,064	2,934,852	6,298,902 419,799	6,718,701	4,198,588	408,806,986 99.29%	2,934,852 0.71%	4,198,588	Carried

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item